<- Back to digest

Arthroscopy - 2026-11-05 - Journal Article

Bone-Patellar Tendon-Bone and Quadriceps Tendon Autografts Are More Cost-Effective Than Hamstring Autograft and Allograft for Anterior Cruciate Ligament Reconstruction.

Dean MC, Hevesi M, Tagliero AJ, Duchman KR, Krych AJ

cost-effectivenessLOE IIIn = N/A5-year modeled time horizon

Topics

sports
PMID: 42989730DOI: 10.1002/arj.70713View on PubMed ->

Key Takeaway

QT and BPTB autografts dominate HS autograft and allograft in cost-effectiveness over 5 years, with QT generating 4.612 QALYs at an ICER of $42,905/QALY versus BPTB and BPTB remaining the least costly option at $3,917.

Summary Depth

Choose how much analysis to show on this article page.

Summary

A decision-analytic Markov model compared 5-year costs and QALYs for BPTB, HS, QT, and allograft ACL reconstruction using time-driven activity-based costing and literature-derived failure probabilities. QT (4.612 QALYs, $4,901) and BPTB (4.589 QALYs, $3,917) dominated HS autograft and allograft in the base case; QT was preferred in 55.7% of probabilistic simulations and BPTB in 44.3%. The preferred strategy between QT and BPTB shifted with a 4.5% reduction in BPTB operative cost or an increase in QT donor-site morbidity from 2.9% to 7.8%.

Key Limitation

The model's preferred strategy between QT and BPTB is highly sensitive to small changes in a single input—QT donor-site morbidity rate (2.9% to 7.8% shifts the decision)—yet this parameter is derived from limited prospective QT-specific data, making the conclusion fragile at the margin.

Original Abstract

PURPOSE

To compare the cost-effectiveness of bone-patellar tendon-bone (BPTB) autograft, hamstring (HS) autograft, quadriceps tendon (QT) autograft, and allograft anterior cruciate ligament reconstruction using contemporary clinical data and time-driven activity-based costing.

METHODS

A decision-analytic Markov model was constructed to compare 5-year costs and quality-adjusted life years (QALYs) for BPTB, HS, QT, and allograft anterior cruciate ligament reconstruction. Probabilities of graft failure, donor-site morbidity, infection, and revision outcomes were derived from contemporary literature. Direct medical costs were obtained from multicenter time-driven activity-based costing data. Model outcomes included costs, QALYs, and the incremental cost-effectiveness ratio. Deterministic and probabilistic sensitivity analyses assessed model robustness across clinically plausible parameter ranges.

RESULTS

QT and BPTB autografts were the highest-value strategies in the model. At a willingness-to-pay threshold of $50,000 per QALY, QT was cost-effective relative to BPTB (incremental cost-effectiveness ratio: $42,905) and showed slightly greater modeled effectiveness; however, BPTB was least costly ($3917 vs $4901) and nearly as effective (4.589 vs 4.612 QALYs). HS autograft and allograft were more costly and less effective in the base-case model. Threshold analyses showed that small changes in operative cost (BPTB decrease of 4.5% or QT increase of 3.7%) or donor-site morbidity (BPTB decrease from 43.0% to 39.9% or QT increase from 2.9% to 7.8%) shifted the preferred strategy from QT to BPTB. In probabilistic sensitivity analyses, QT was preferred in 55.7% of simulations and BPTB was favored in the remaining 44.3%, with QT dominant in 22.4% of simulations.

CONCLUSIONS

QT and BPTB autografts offered the highest value for anterior cruciate ligament reconstruction, with QT slightly more effective and BPTB least costly. HS autograft and allograft were more costly and less effective. Given the sensitivity of these results to surgeon-specific factors, operative costs, and donor-site morbidity, graft selection should remain individualized based on patient goals, clinical considerations, and surgeon expertise rather than cost alone.

LEVEL OF EVIDENCE

Level III, economic and decision analysis.